Drug Type Recombinant polypeptide |
Synonyms EP-302 |
Target |
Mechanism NCL inhibitors(Nucleolin inhibitors), Th1 cells stimulants(Th1 cells stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | US | 18 Aug 2022 | |
Neoplasms | Preclinical | US | 15 Apr 2010 |